Biofarma: UNICEF Orders 200 Million Indonesian Polio Vaccines

UNICEF ordered the nOPV2 vaccine made by Bio Farma with the latest technology.

REPUBLIKA.CO.ID, JAKARTA — The United Nations Children’s Fund (UNICEF) has ordered a total of 200 million doses polio vaccine The production of PT Biofarma is called the novel Oral Polio Vaccine type 2 (nOPV2). This number has been ordered throughout 2020-2021.

Bio Farma’s Head of Corporate Communication Iwan Setiawan said that nOPV2 is the latest type of polio vaccine in the world which is intended for a number of countries that are still struggling with polio outbreaks. The countries in question include those domiciled in the Eastern Mediterranean, Western Pacific, and several regions in Southeast Asia.

“One of them is Africa which is still struggling with polio outbreaks, because there are still many countries in the region that have not been free from polio,” he said.

Iwan said the production of the vaccine was adjusted to the number of requests from Indonesia Unicef when a country is experiencing a spike in cases. Once the vaccine is ordered, Unicef ​​will distribute it to a number of countries in need.

According to Iwan, the order for the vaccine made by Bio Farma was based on WHO’s approval for the use of the Polio vaccine in an emergency (Emergency Use Listing/EUL) on November 13, 2020. Iwan said nOPV2 is a modified version of the existing monovalent type 2 OPV (mOPV2). .

In clinical trials, nOPV2 provides the same protection against type 2 poliovirus with the advantage of being more genetically stable. The use of nOPV2 in this EUL condition, said Iwan, has been recommended by the Strategic Advisory Group of Experts (SAGE) on Immunization, an independent institution that recommends nOPV2 to overcome the Polio outbreak and also the Global Polio Eradication Initiative (GPEI) to ensure that during the EUL period, attention is paid to safety standards.

“The world’s progress against the polio epidemic has been 99.9 percent since the last 30 years, but this epidemic is difficult to eradicate,” he said.

President Director of Bio Farma Honesti Basyir said before the issuance of the EUL from WHO, the Food and Drug Supervisory Agency (BPOM) had issued an Emergency Use Authorization Limited to conditions of a pandemic outbreak for 50 doses of nOPV2. Bio Farma is also conducting clinical trials of nOPV2 in several places, namely Belgium and Panama.

Bio Farma is required to conduct a phase 3 clinical study to ensure the effectiveness and safety of the vaccine as an active poliomyelitis type 2 immunization. for the manufacture of the nOPV2 vaccine.

source: between



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.